Il mercato dei neoantigeni è stato valutato a 2.71.428,57 migliaia di dollari nel 2023 e si prevede che raggiungerà 10.54.783,54 migliaia di dollari entro il 2028; si prevede che crescerà a un CAGR del 31,2% dal 2023 al 2028.
I neoantigeni sono antigeni sviluppati di recente che storicamente non sono stati rilevati dal sistema immunitario. Le alterazioni delle proteine tumorali possono comportare lo sviluppo di neoantigeni causati da mutazioni o proteine virali. I neoantigeni sono utilizzati in trattamenti selettivi per le cellule cancerose.
Il mercato dei neoantigeni è segmentato in base al trattamento, alla specialità terapeutica e alla geografia. In base alla geografia, il mercato è segmentato in Nord America, Europa, Asia Pacifico, Medio Oriente e Stati Uniti. Africa e America meridionale e centrale. Il rapporto offre approfondimenti e analisi approfondite del mercato dei neoantigeni sottolineando vari parametri quali tendenze del mercato, progressi tecnologici, dinamiche di mercato e analisi del panorama competitivo dei principali attori del mercato in tutto il mondo. Include anche l’analisi dell’impatto del COVID-19 in tutte le regioni. Si stima che il mercato avrà probabilmente un tasso di crescita costante durante il periodo di previsione.
Approfondimenti di mercato
Sviluppi dei vaccini neoantigeni contro Cancro
Gli sviluppi nel campo della biotecnologia hanno portato ad una maggiore accettazione dell'immunoterapia, spingendone ulteriormente l'uso nelle medicine personalizzate. L’immunoterapia è ampiamente utilizzata per trattare il cancro; alcune procedure immunoterapeutiche prevedono l'utilizzo di neoantigeni, gli antigeni presenti sulla superficie delle cellule tumorali. Pertanto, le applicazioni dei neoantigeni sono ampiamente studiate per il trattamento del cancro. L'unicità dei neoantigeni consente ai ricercatori di identificare i risultati dei pazienti’ immunitario e trovare antigeni per colpire le cellule tumorali senza disturbare le cellule sane.
Gli sviluppi nell'immunoterapia hanno preso piede dopo il 2015, quando è stata eseguita la prima sperimentazione clinica del vaccino neoantigenico. Nel 2017, Neon Therapeutics ha pubblicato due ulteriori studi clinici che hanno dimostrato l'efficacia del vaccino neoantigenico nel trattamento del melanoma (cancro della pelle) negli esseri umani. I risultati positivi degli studi clinici hanno attratto varie start-up nella scoperta e nello sviluppo di terapie antitumorali basate sui neoantigeni. Molte aziende hanno mostrato interesse per lo sviluppo di neoantigeni. Di seguito sono riportati alcuni esempi di aziende coinvolte nello sviluppo di neoantigeni.
- BioNTech SE è un'azienda tedesca che opera nel mercato dei vaccini neoantigeni. BioNTech SE ha sviluppato la piattaforma Mutanome di vaccini individualizzati contro il cancro (IVAC) che ingegnerizza molecole di RNA per produrre un vaccino neoantigenico personalizzato. Gli studi clinici per l'IVAC mirati al cancro al seno triplo negativo, a più tipi di tumore e al melanoma sono in corso.
- La piattaforma ATLAS di Genocea Biosciences utilizza un metodo ex-vivo per sviluppare neoantigeni vaccini. Genocea Biosciences ha raccolto fondi per circa 91 milioni di dollari da investitori come Polaris Partners, GlaxoSmithKline e Johnson & Johnson Innovation svilupperà il suo vaccino contro il cancro neoantigenico—GEN-009. Attualmente in fase di sperimentazione clinica di Fase 1a/2, il vaccino è progettato per trattare melanoma, cancro ai polmoni e carcinomi.
- Gritstone Oncology utilizza la sua piattaforma AI, EDGE, per sviluppare vaccini neoantigenici utilizzando un in -approccio silico. L'azienda ha sviluppato due prodotti GRANITE-001 e SLATE-001. GRANITE-001 è concepito come trattamento individuale basato sul tipo di tumore specifico del paziente, mentre SLATE-001 è formulato come un vaccino neoantigenico comune che può essere utilizzato per più pazienti che mostrano neoantigeni simili.
- Agenus Inc. ha sviluppato il vaccino neoantigenico AutoSynVax (ASV) che viene somministrato con uno stimolo adiuvante QS-21 per il trattamento dei tumori solidi. Attualmente ASV è nella sperimentazione clinica di Fase 1 negli Stati Uniti.
- Dal 2016, Moderna, Inc. è coinvolta in studi clinici per il suo vaccino personalizzato contro il cancro (PCV) mRNA-4157 in combinazione con Keytruda di Merck. Nel novembre 2020, Moderna, Inc. ha pubblicato aggiornamenti sui suoi vaccini antitumorali affermando che la somministrazione di mRNA-4157 in combinazione con Keytruda è ben tollerata a tutti i livelli di dose e ha prodotto risposte nei pazienti.
Tale gli sviluppi dei vaccini neoantigeni contro il cancro stanno alimentando la crescita del mercato.
Approfondimenti basati sul trattamento
In base al trattamento, il mercato dei neoantigeni è segmentato in terapia combinata e monoterapia. Si stima che nel 2023 il segmento della terapia combinata avrà una quota di mercato maggiore. Tuttavia, si prevede che il segmento della monoterapia avrà una crescita più rapida durante il periodo di previsione.
Mercato globale dei neoantigeni, per trattamento: 2020 e 2028Approfondimenti basati sulla specialità terapeutica
Sulla base della specialità terapeutica, il mercato dei neoantigeni è segmentato in cancro gastrointestinale, cancro ai polmoni, tumore solido, sistema urinario tumori, melanoma, cancro della testa e del collo e altri. Si stima che nel 2023 il segmento del cancro gastrointestinale deterrà la quota maggiore del mercato e si prevede che crescerà al ritmo più rapido nei prossimi anni.
Approfondimenti strategici< /p>
Le strategie inorganiche sono state ampiamente adottate dagli attori del mercato per soddisfare la mutevole domanda dei clienti e mantenere i loro servizi migliorati. Ad esempio, nel gennaio 2021, Genocea annuncia la pubblicazione della scoperta del cancro grazie ai vantaggi dell'identificazione dei neoantigeni utilizzando la piattaforma ATLAS. Questa scoperta rafforza le immunoterapie con neoantigeni garantendo teoricamente che abbiano come bersaglio i neoantigeni corretti rimuovendo al contempo gli inibitori.
Per trattamento
- Terapia di combinazione
- Monoterapia
Per specialità terapeutica
- Cancro gastrointestinale
- Cancro ai polmoni
- Solido Tumori
- Tumori del sistema urinario
- Melanoma
- Tumori della testa e del collo
- Altri
Di Geografia
- Nord America
- Stati Uniti
- Canada
- Messico
- Europa
- Francia
- Germania
- Italia
- Regno Unito
- Spagna
- Resto del Europa
- Asia Pacifico (APAC)
- Cina
- India
- Corea del Sud < li>Giappone
- Australia
- Resto dell'APAC
- Sudafrica
- Arabia Saudita
- EAU
- Resto del MEA
- Brasile
- Argentina
- Resto dello SCAM
Profili aziendali
- Achilles Therapeutics plc
- Advaxis, Inc.
- Frame Cancer Therapeutics
- Genocea, Gradalis, Inc.
- Gritstone Oncology
- Immunicum AB
- Medigene AG
- Ziopharm Oncology, Inc.
- Moderna, Inc.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Neoantigens are recently developed antigens that have not been detected by the immune system historically. Alterations in tumor proteins may result in the development of neoantigens caused by mutations or viral proteins. Neoantigens are used in selective treatments for cancerous cells.
Key factors that are driving growth of the market are developments in neoantigen vaccines against cancer and increasing prevalence of cancer. However, possible side effects associated with neoantigen vaccines are likely to hinder the growth of the neoantigens market.
Several companies into clinical trial phases for their respective neoantigens. It is expected that by 2023, companies will commercialize their products in the market. In addition, it is expected that the cost of neoantigens will be much higher than cancer vaccines.
The List of Companies - Neoantigens Market
- Achilles Therapeutics plc
- Advaxis, Inc.
- Frame Cancer Therapeutics
- Genocea
- Gradalis, Inc.
- Gritstone Oncology
- Immunicum AB
- Medigene AG
- Ziopharm Oncology, Inc.
- Moderna, Inc.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
May 2021
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
May 2021
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
May 2021
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
May 2021
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
May 2021
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
May 2021
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
May 2021
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
May 2021
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)